Janney Montgomery Scott LLC Sells 1,007 Shares of Sanofi (NASDAQ:SNY)

Janney Montgomery Scott LLC lessened its position in Sanofi (NASDAQ:SNY) by 0.3% in the third quarter, HoldingsChannel.com reports. The fund owned 309,352 shares of the company’s stock after selling 1,007 shares during the period. Janney Montgomery Scott LLC’s holdings in Sanofi were worth $17,828,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Manning & Napier Advisors LLC acquired a new position in shares of Sanofi in the second quarter valued at $13,725,000. Mount Yale Investment Advisors LLC raised its holdings in Sanofi by 44.3% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after acquiring an additional 12,806 shares during the period. Jennison Associates LLC lifted its position in Sanofi by 18.9% during the first quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock worth $9,216,000 after acquiring an additional 30,115 shares during the last quarter. Sei Investments Co. boosted its holdings in shares of Sanofi by 9.3% during the first quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock worth $26,926,000 after acquiring an additional 47,297 shares during the period. Finally, Atria Investments Inc grew its position in shares of Sanofi by 31.1% in the first quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock valued at $4,805,000 after purchasing an additional 23,463 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Argus raised their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $57.50.

Sanofi Price Performance

Sanofi stock opened at $52.85 on Wednesday. The firm has a market cap of $134.12 billion, a PE ratio of 26.96, a price-to-earnings-growth ratio of 1.36 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock’s fifty day moving average price is $55.85 and its two-hundred day moving average price is $52.10. Sanofi has a one year low of $45.00 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter last year, the business earned $2.55 earnings per share. Sanofi’s revenue was up 12.3% on a year-over-year basis. As a group, research analysts expect that Sanofi will post 4.27 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.